Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/14/2023 | $47.50 | Overweight | Morgan Stanley |
| 8/10/2023 | $70.00 | Overweight | Cantor Fitzgerald |
| 3/2/2022 | $194.00 → $102.00 | Outperform | SVB Leerink |
| 1/21/2022 | $64.00 | Outperform | Macquarie |
| 12/15/2021 | $189.00 → $136.00 | Overweight | JP Morgan |
| 11/11/2021 | $222.00 → $217.00 | Buy | Citigroup |
| 11/10/2021 | $200.00 → $194.00 | Outperform | SVB Leerink |
| 10/12/2021 | Market Perform | Bernstein |
4 - Zai Lab Ltd (0001704292) (Issuer)
4 - Zai Lab Ltd (0001704292) (Issuer)
4 - Zai Lab Ltd (0001704292) (Issuer)
- Company to host conference call and webcast on February 27, at 8:00 a.m. ET (9:00 p.m. HKT) Zai Lab Limited (NASDAQ:ZLAB, HKEX: 9688)) today announced that it will report its fourth quarter and full year 2024 financial results and provide recent corporate updates on February 27, 2025, before the opening of the U.S. equity markets. The announcement will be followed by a conference call and webcast at 8:00 a.m. ET (9:00 p.m. HKT). Conference Call and Webcast Information Listeners may access the live webcast by visiting the Company's website at http://ir.zailaboratory.com. Participants must register in advance of the conference call. Details are as follows: Registration Link: https
Zai Lab Limited (NASDAQ:ZLAB, HKEX: 9688)) today announced the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to ZL-1310, a potential highly active first-in-class DLL3 antibody-drug conjugate (ADC), for the treatment of small cell lung cancer (SCLC). "Receiving an Orphan Drug Designation for ZL-1310 recognizes its potential to treat patients with SCLC. These patients have an urgent need for innovative treatment options with improved efficacy, safety and ready access in tertiary care and community settings," said Rafael G. Amado, M.D., President, Head of Global Research and Development, Zai Lab. "ZL-1310 has demonstrated promising objective response rates
Zai Lab Limited (NASDAQ:ZLAB, HKEX: 9688)) today announced that China's National Medical Products Administration (NMPA) has accepted the New Drug Application (NDA) for KarXT for the treatment of schizophrenia in adults. "There are more than 8 million patients living with schizophrenia in China who face significant unmet needs due to the limited efficacy and undesirable side effects of current treatment options," said Dr. Rafael Amado, M.D., President, Head of Global Research and Development at Zai Lab. "In clinical trials, KarXT demonstrated statistically significant reductions of schizophrenia symptoms along with a tolerable safety profile. If approved, KarXT has the potential to redefin
SC 13G - Zai Lab Ltd (0001704292) (Subject)
SC 13G/A - Zai Lab Ltd (0001704292) (Subject)
SC 13G/A - Zai Lab Ltd (0001704292) (Subject)
SCHEDULE 13G/A - Zai Lab Ltd (0001704292) (Subject)
SCHEDULE 13G - Zai Lab Ltd (0001704292) (Subject)
SCHEDULE 13G/A - Zai Lab Ltd (0001704292) (Subject)
Morgan Stanley initiated coverage of Zai Lab with a rating of Overweight and set a new price target of $47.50
Cantor Fitzgerald initiated coverage of Zai Lab with a rating of Overweight and set a new price target of $70.00
SVB Leerink reiterated coverage of Zai Lab with a rating of Outperform and set a new price target of $102.00 from $194.00 previously
4 - Zai Lab Ltd (0001704292) (Issuer)
4 - Zai Lab Ltd (0001704292) (Issuer)
4 - Zai Lab Ltd (0001704292) (Issuer)
Zai Lab Limited (NASDAQ:ZLAB, HKEX: 9688))) announced today that following a distinguished career, Harald Reinhart, M.D., President, Head of Global Development, Neuroscience, Autoimmune and Infectious Diseases (NSAiID) of Zai Lab, will retire at the end of June, after which he will serve as a senior advisor for the Company. Rafael Amado, M.D., President, Head of Global Oncology Research and Development of Zai Lab, will expand his role and assume responsibility for all of the Company's Global R&D upon Dr. Reinhart's retirement. "Harald has devoted nearly 50 years to treating patients, first as a physician and later discovering and developing innovative therapies to bring to patients in
SHANGHAI and CAMBRIDGE, Mass., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ:ZLAB, HKEX: 9688))) today announced that Michel Vounatsos has been appointed to its Board of Directors, effective January 7, 2023. Mr. Vounatsos brings to the Board extensive global leadership and management experience in the biopharmaceutical industry, including more than 25 years of service at leading companies. His expertise includes significant commercial experience in China and worldwide in the areas of primary care and neuroscience. "We are delighted to welcome Michel Vounatsos to the Zai Lab Board of Directors," said Dr. Samantha Du, Founder, Chairperson, and CEO of Zai Lab. "Michel has a wealt
SHANGHAI and CAMBRIDGE, Mass., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ:ZLAB, HKEX: 9688))) a patient-focused, innovative, commercial-stage, global biopharmaceutical company, today announced the appointment of Rafael G. Amado, M.D. as President, Head of Global Oncology Research and Development, effective December 30, 2022. Dr. Amado brings to Zai Lab deep expertise in the field of oncology and significant global biopharmaceutical R&D leadership. "We are pleased to welcome Rafael to our executive leadership team," said Dr. Samantha Du, Founder, Chairperson, and CEO of Zai Lab. "Rafael's experience leading worldwide discovery and clinical development for a number of oncolog
- Company to host conference call and webcast on February 27, at 8:00 a.m. ET (9:00 p.m. HKT) Zai Lab Limited (NASDAQ:ZLAB, HKEX: 9688)) today announced that it will report its fourth quarter and full year 2024 financial results and provide recent corporate updates on February 27, 2025, before the opening of the U.S. equity markets. The announcement will be followed by a conference call and webcast at 8:00 a.m. ET (9:00 p.m. HKT). Conference Call and Webcast Information Listeners may access the live webcast by visiting the Company's website at http://ir.zailaboratory.com. Participants must register in advance of the conference call. Details are as follows: Registration Link: https
Strong growth in net product revenue of 47% y-o-y to reach $101.8 million for the third quarter of 2024 Positive China bridging study of KarXT in schizophrenia; expected regulatory submission in early 2025 Global Phase 1 data of ZL-1310 (DLL3 ADC) suggests best-in-class potential in extensive-stage SCLC Three product launches in mainland China expected by the end of 2024, and up to four potential regulatory submissions to the NMPA in the next six months Strong balance sheet with a cash position1 of $716.1 million as of September 30, 2024, compared to $730.0 million as of June 30, 2024 Conference call and webcast today, November 12, at 8:00 a.m. ET (9:00 p.m. HKT) Zai Lab L
-- Objective response rate (ORR) of 74% across all tested dose levels of ZL-1310 in patients with recurrent extensive-stage small cell lung cancer (SCLC) -- Favorable pharmacokinetics (PK) and safety profile support continued evaluation of ZL-1310 as a single agent and in combination for the treatment of extensive-stage SCLC in recurrent and first-line therapy -- Zai Lab to host conference call and webcast to discuss data on October 24, 2024, at 8:30 a.m. ET, following presentation of the data at ENA Zai Lab Limited (NASDAQ:ZLAB, HKEX: 9688))) today presented data from the ongoing global Phase 1a/1b study of ZL-1310, a potential best-in-class next-generation antibody-drug conjugate (ADC)